Lataa...
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially...
Tallennettuna:
| Julkaisussa: | Am J Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
e-Century Publishing Corporation
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126281/ https://ncbi.nlm.nih.gov/pubmed/27904779 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|